SentienBiotech
@SentienBiotech
Followers
228
Following
126
Statuses
136
Sentien Biotechnologies, Inc. is a privately owned, clinical-stage company developing novel approaches to cell therapy.
Joined April 2017
RT @McmahonBlaithin: SB-101 running in series w HF1400 filter to allow sustained 24hr delivery of regenerative products from human mesenchy…
0
1
0
@SentienBiotech is @alliancerm's Cell & Gene Meeting on the Mesa in Carlsbad, CA! CEO Brian Miller to present on Sentien's ex vivo MSC therapy, SBI-101, on Wednesday Oct 13 at 2:30pm. #CGMesa21 #MSC #celltherapy
0
0
4
RT @JFruehauf: Congratulations @sentienbiotech team for this publication and important progress with your work. Restoring balance to the im…
0
1
0
@SentienBiotech reports promising results in @StemCellsTM publication on our ex vivo MSC therapy, SBI-101, for the treatment of acute kidney injury!
0
0
1
RT @mswami001: Thanks to the efforts of my co-authors at @SentienBiotech and around the country! Pharmacological effects of ex vivo mesenc…
0
5
0
Read @SentienBiotech's new publication with data from our first Ph I/II study of SBI-101 in subjects with AKI! Data supports the therapeutic hypothesis that ex vivo delivery of MSC-secreted factors leads to immunomodulation & reprogramming of immune cells
0
2
5
@SentienBiotech has received an award from @MD_Stem_Cell to help fund Sentien's clinical study of SBI-101 for the treatment of acute kidney injury associated with sepsis (including from #COVID19)! #celltherapy #MSC
.@MD_Stem_Cell Research Commission Announces $1M in 3 New Awards to Accelerate Cures For: • Primary Immunodeficiencies/Inherited Bone Marrow Failures • Craniofacial/Bone Defects • Sepsis/Acute Kidney Injury Read Press Release: #biotech #health
0
0
2
@SentienBiotech is excited to be partnering with @BARDA to evaluate our cell-based therapeutic, SBI-101, for its ability to improve clinical outcomes for patients with #sepsis, including from #COVID19! @WorldSepsisDay @SepsisAlliance
This #WorldSepsisDay, find out more about our all-of-BARDA approach to address sepsis:
0
0
1
@SentienBiotech Partners with @BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis, Including from #COVID19 via @PRWeb
0
1
2
RT @BARDA: With #DRIVeInnovation support, @SentienBiotech is evaluating SBI-101, a cell based therapeutic, for its ability to improve clini…
0
4
0
Tune in now as @SentienBiotech VP of R&D, Dr. Rita Barcia, is interviewed on ISCT TV! @ISCTglobal #COVID19 #MSC #celltherapy
0
1
4
Check out @SentienBiotech's upcoming presentations at #ISCT2021! Dr. Rita Barcia, VP of R&D, will share early data from our Ph1/2 trial of SBI-101 for the treatment of severe #COVID19 & will be featured during an interview session on ISCT TV on 5/26! #celltherapy #MSC @ISCTglobal
0
1
4
Register for this webinar on Wed 4/28 with @SentienBiotech VP of R&D, Dr. Rita Barcia, discussing considerations for #MSC product and process development through clinical cGMP manufacturing, alongside other distinguished panelists! @RoosterBio @jan_nolta
Don't miss next week's webinar on key considerations for hMSC product and process development through clinical cGMP manufacturing (April 28th, 11am ET); @CGT_Insights #CellTherapy
0
3
5
@SentienBiotech Completes Enrollment of First Cohort in Ph 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19 via @PRWeb #COVID19 #celltherapy #MSC
0
4
8
@SentienBiotech's new publication highlights the ability of our ex-vivo cell therapy approach to reduce clotting in vitro, an important advantage relative to IV delivery. Particularly relevant in treating #COVID19 patients who tend to be hypercoagulable.
0
1
3
University of New Mexico physicians Dr. J. Pedro Teixeira & Dr. Christos Argyropoulos discuss enrolling the first subject in @SentienBiotech's Ph 1/2 study of SBI-101, our ex vivo MSC therapy, for the treatment of severe #COVID19! @ChristosArgyrop @NephCrit_NM @gtrejoleal
New experimental COVID treatment happening at UNM
0
2
9
@SentienBiotech Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19 via @PRWeb @ChristosArgyrop @NephCrit_NM @gtrejoleal #COVID19 #celltherapy #MSC
0
4
8
Check out @SentienBiotech CEO Brian Miller's presentation from the @alliancerm Cell & Gene Meeting on the Mesa!
0
2
4